Insights

Innovative Technology Licensing Halozyme's proprietary ENHANZE® technology and enzyme rHuPH20 form the foundation for advanced drug delivery solutions, creating opportunities for collaborations with pharmaceutical companies seeking to enhance their injectable therapies.

Strategic Acquisitions The company's plan to acquire Elektrofi Inc. for up to $900 million positions Halozyme as a key player in the subcutaneous drug delivery space, opening avenues for cross-selling and expanding product offerings to existing partners.

Strong Industry Partnerships Halozyme’s collaborations with major pharma players like Roche, Pfizer, and Bristol-Myers Squibb demonstrate its established reputation and potential to expand licensing agreements and joint development projects.

Growth-Focused Financing With recent financing of $1.3 billion, Halozyme is well-positioned to fund ongoing R&D and strategic initiatives, enabling sales teams to leverage a financially robust company for long-term partnership opportunities.

Expanding Product Pipeline The company's development of new formulations such as subcutaneous petosemtamab indicates potential opportunities to introduce or co-develop innovative therapies with partners in emerging fields.

Similar companies to Halozyme, Inc.

Halozyme, Inc. Tech Stack

Halozyme, Inc. uses 8 technology products and services including Cookiebot, NetSuite, Wireshark, and more. Explore Halozyme, Inc.'s tech stack below.

  • Cookiebot
    Cookie Compliance
  • NetSuite
    E-commerce
  • Wireshark
    IT Infrastructure Monitoring
  • DocuSign
    Miscellaneous
  • Datto
    Security
  • Onsen UI
    Software Development
  • Google Tag Manager
    Tag Management
  • Apache HTTP Server
    Web Servers

Media & News

Halozyme, Inc.'s Email Address Formats

Halozyme, Inc. uses at least 1 format(s):
Halozyme, Inc. Email FormatsExamplePercentage
FLast@halozyme.comJDoe@halozyme.com
89%
Last@halozyme.comDoe@halozyme.com
5%
First.Last@halozyme.comJohn.Doe@halozyme.com
5%
LFirst@halozyme.comDJohn@halozyme.com
1%

Frequently Asked Questions

What is Halozyme, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Halozyme, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Halozyme, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Halozyme, Inc.'s official website is halozyme.com and has social profiles on LinkedInCrunchbase.

How much revenue does Halozyme, Inc. generate?

Minus sign iconPlus sign icon
As of December 2025, Halozyme, Inc.'s annual revenue is estimated to be $135M.

What is Halozyme, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Halozyme, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Halozyme, Inc. have currently?

Minus sign iconPlus sign icon
As of December 2025, Halozyme, Inc. has approximately 470 employees across 6 continents, including North AmericaAsiaEurope. Key team members include CEO: H. T.Chief Commercial Officer (cco): P. S.Chief Commercial Officer: B. H.. Explore Halozyme, Inc.'s employee directory with LeadIQ.

What industry does Halozyme, Inc. belong to?

Minus sign iconPlus sign icon
Halozyme, Inc. operates in the Biotechnology Research industry.

What technology does Halozyme, Inc. use?

Minus sign iconPlus sign icon
Halozyme, Inc.'s tech stack includes CookiebotNetSuiteWiresharkDocuSignDattoOnsen UIGoogle Tag ManagerApache HTTP Server.

What is Halozyme, Inc.'s email format?

Minus sign iconPlus sign icon
Halozyme, Inc.'s email format typically follows the pattern of FLast@halozyme.com. Find more Halozyme, Inc. email formats with LeadIQ.

How much funding has Halozyme, Inc. raised to date?

Minus sign iconPlus sign icon
As of December 2025, Halozyme, Inc. has raised $500M in funding. The last funding round occurred on Aug 15, 2022 for $500M.

Halozyme, Inc.

Biotechnology ResearchCalifornia, United States201-500 Employees

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with ENHANZE®. 

We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values. 

We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details.   

We are Halozyme.

Section iconCompany Overview

Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
201-500

Section iconFunding & Financials

  • $500M

    Halozyme, Inc. has raised a total of $500M of funding over 7 rounds. Their latest funding round was raised on Aug 15, 2022 in the amount of $500M.

  • $500M$1B

    Halozyme, Inc.'s revenue is estimated to be in the range of $500M$1B

Section iconFunding & Financials

  • $500M

    Halozyme, Inc. has raised a total of $500M of funding over 7 rounds. Their latest funding round was raised on Aug 15, 2022 in the amount of $500M.

  • $500M$1B

    Halozyme, Inc.'s revenue is estimated to be in the range of $500M$1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.